An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease

Brain

Volumn 119, Issue 2, 1996, Pages 585-591

  Morrish, P K ^a   Sawle, G V ^c   Brooks, D J ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Parkinson's disease; PET; Progression; 18F dopa

Indexed keywords

DIAGNOSTIC AGENT; DOPA; FLUORINE; FLUORINE 18;

AGED; ANALYSIS OF VARIANCE; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; MALE; MIDDLE AGED; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROGNOSIS; PUTAMEN; SCINTISCANNING; ADULT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; FOLLOW UP; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RATING SCALE;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; DIHYDROXYPHENYLALANINE; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PROGNOSIS; PUTAMEN; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0029981856     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/119.2.585     Document Type: Article

References (26)

1. Altman DG. Practical statistics for medical research. London: Chapman and Hall. 1991-456.
2. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations. J Neurol Sci 1973; 20: 415-55.
3. Brooks DJ, Salmon EP, Mathias CJ, Quinn N, Leenders KL, Bannister R, et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomie failure, and Parkinson's disease, studied with PET. Brain 1990; 113: 1539-52.
4. Eidelberg D, Takikawa S, Dhawan D, Chaly T, Robeson W, Dahl R, et al. Striatal 18F-dopa uptake: absence of an aging effect [see comments]. J Cereb Blood Flow Metab 1993; 13: 881-8. Comment in: J Cereb Blood Flow Metab 1994; 14: 882-3.
5. Eidelberg D, Takikawa S, Dhawan D, Chaly T, Robeson W, Dahl R, et al. Striatal 18F-dopa uptake: absence of an aging effect [see comments]. J Cereb Blood Flow Metab 1993; 13: 881-8. Comment in: J Cereb Blood Flow Metab 1994; 14: 882-3.
6. Fahn S, Elton RL. Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson's disease. Florham Park (NJ): MacMillan Healthcare Information, 1987: 153-63.
7. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283-301.
8. Flaherty AW, Graybiel AM. Anatomy of the basal ganglia. In: Marsden CD, Fahn S, editors. Movement disorders 3. Oxford: Butterworth-Heinemann, 1994: 3-27.
9. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. [Review]. J Neurol Neurosurg Psychiatry 1988; 51: 745-52.
10. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-12.
11. Koller WC. When does Parkinson's disease begin? [Review]. Neurology 1992; 42 (4 Suppl 4): 27-31.
12. Koller WC, Langston JW, Hubble JP, Irwin I, Zack M, Golbe L, et al. Does a long preclinical period occur in Parkinson's disease? [Review]. Neurology 1991; 41 (5 Suppl 2): 8-13.
13. McGeer PL, Itagaki S, Akiyama H, McGeer EG. Rate of cell death in Parkinsonism indicates active neuropathological process. Ann Neurol 1988; 24: 574-6.
14. Morrish PK, Sawle GV, Brooks DJ. Clinical and [18F]dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1995; 59: 597-600.
15. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3: 1-7.
16. Robb RA, Hanson DP. A software system for interactive and quantitative visualization of multidimensional biomedical images. Australas Phys Eng Sci Med 1991; 14: 9-30.
17. Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RSJ. Striatal function in normal aging: implications for Parkinson's disease. Ann Neurol 1990; 28: 799-804.
18. Sawle GV, Burn DJ, Morrish PK, Lammertsma AA, Snow BJ, Luthra S, et al. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology 1994; 44: 1292-7.
19. Scheffé H. The analysis of variance. New York: Wiley, 1959: 221-60.
20. Snow BJ, Tooyama I, McGeer EG, Yamada T, Calne DB, Takahashi H, et at. Human positron emission tomographic [18F] fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993; 34: 324-30.
21. Spinks T, Jones T, Heather J, Gilardi M. Quality control pocedures in positron tomography. Eur J Nucl Med 1989; 15: 736-40.
22. Takikawa S, Dhawan V, Chaly T, Robeson W, Dahl R, Zanzi I, et al. Input functions for 6-(fluorine-18)fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations. J Nucl Med 1994; 35: 955-63.
23. Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. Stuttgart: G. Thieme, 1988.
24. Vingerhoets FJG, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 1994a; 36: 759-64.
25. Vingerhoets FJ, Snow BJ, Schulzer M, Morrison S, Ruth TJ, Holden JE, et al. Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects [see comments]. J Nucl Med 1994b; 35: 18-24. Comment in: J Nucl Med 1994; 35: 24-6.
26. Vingerhoets FJ, Snow BJ, Schulzer M, Morrison S, Ruth TJ, Holden JE, et al. Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects [see comments]. J Nucl Med 1994b; 35: 18-24. Comment in: J Nucl Med 1994; 35: 24-6.